Phase 3 Pancreatitis Trial, Recruiting NCT05252754 Sponsor: Johns Hopkins University Condition: Pancreatitis
Back to Pancreatitis

Phase 3 Pancreatitis Trial, Recruiting

NCT05252754
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are at least 18 years old
  • You are already scheduled to have a procedure called an ERCP (a scope procedure used to examine and treat the bile ducts and pancreas) at one of the participating hospitals
  • You are willing and able to give your consent to take part in the study

Who may not be able to join:

  • You are unwilling or unable to give consent to take part
  • You are currently pregnant
  • You are currently breastfeeding
  • You have a long-term condition called chronic calcific pancreatitis (a type of lasting pancreas damage with calcium deposits)
  • Your ERCP is being done only to swap out or remove a previously placed tube (biliary stent)
  • You have had a previous cutting procedure on your bile duct opening and your ERCP is not expected to involve imaging of the pancreas (confirm with trial site)
  • You have a condition called pancreas divisum (an abnormality in how the pancreas formed) and you are having a bile duct procedure
  • You have a medical reason why you cannot take tacrolimus (an immune-suppressing drug) or anti-inflammatory painkillers like ibuprofen
  • You are currently taking tacrolimus or any other immune-suppressing medication
  • You have significant kidney disease or sudden kidney injury (confirm with trial site for specific kidney function levels)
  • You do not have a rectum (the lower part of the large intestine)
  • You have had a pancreas inflammation episode (acute pancreatitis) within the last 30 days
  • You have a cancerous tumour in the head of the pancreas
  • You have been diagnosed with a specific bile duct muscle disorder called Sphincter of Oddi dysfunction Type 3

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Venkata S. Akshintala, M.D., Johns Hopkins University

Phone: +1 (410) 614-6708

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
18 January 2023
Est. completion
1 December 2026

Where this trial is recruiting

🇮🇳 India 🇸🇬 Singapore 🇺🇸 United States

Primary endpoints

The proportion of subjects in each study group with Post ERCP Acute Pancreatitis (PEP)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov